Chul Kim
@chulkimMD
Thoracic Medical Oncologist at Georgetown University / Lung Cancer, Thymic Tumors, Phase I / #SoMeEditor @ClinicalLung | #LCSM
"After 20 years of leadership, @marshalj23, will be stepping down as the division chief of Medical Oncology at MedStar Georgetown University Hospital. Dr. Marshall will remain in practice with our GI oncology disease group and will continue to serve as the chief medical officer…
💨🧬🫁 The mutagenic forces shaping the genomes of lung cancer in never smokers. #LCSM nature.com/articles/s4158…
#ALK is a viable target even in squamous NSCLC, demonstrated by this case + review in @ClinicalLung. However, significant variability in quality of response. While most respond, many brief courses of crizotinib, one on 1L alectinib for 5y and counting. clinical-lung-cancer.com/article/S1525-…
At NOSCM, @JuliaRotow presents provocative data supporting continuation of EGFR TKIs after progressive disease, so-called treatment beyond progression (TBP). I am increasingly a believer. Invariably there are residual sensitive clones which need to be controlled
v2025.1 @ASCO Living Guideline for stage 4 NSCLC w/o driver mutation out now in @JCO_ASCO. key updates: ✅commentary of ph3 NIPPON trial and HARMONI-2 trial ✅commentary of ph3 DUBLIN-3 trial consider downloading the @ASCO Guidelines Podcast for a concise summary of this update!
Update to the @ASCO Living Guidelines for NSCLC with driver alterations now @JCO_ASCO from @Joshua_Reuss et al to include zenocutuzumab for patients with NSCLC that harbors an #NRG1 fusion. ascopubs.org/doi/10.1200/JC…
Out now in @JCO_ASCO, v2025.1 of @ASCO Living Guideline for Stage 4 NSCLC w/ driver mutation. ascopubs.org/doi/pdf/10.120…. key updates: ✅incorporation of zenocutuzumab for NRG1-fusion+ NSCLC. ✅commentary on ph2 RAMOSE trial. For concise summary, ✔️ out @ASCO guidelines podcast
Excited to join the upcoming webinar, "Understanding Clinical Trials: A Fireside Chat with Experts & Survivors," organized by the Ralph Lauren Center for Cancer Prevention @LombardiCancer & @LUNGevity! 🗓️ July 15, 2025 | 🕕 6–7 PM EDT 🔗 Register here: bit.ly/40KsenA
3y f/u from Italian Phase IIIB MAURIS trial @ClinicalLung - 1L carboplatin + etoposide + atezolizumab in a broader, real-world population. 1y OS rate 45.5%, 2y OS rate 31.0%, 3y OS rate 14.5%, mOS 10.6m, mPFS 5.5m. clinical-lung-cancer.com/article/S1525-…
Honored and humbled to accept a new role as Division Chief for Hematology & Oncology at Georgetown starting next month. Excited for all that the future holds for @Georgetown @LombardiCancer with the best colleagues one could ask for.
Dr. Chul Kim from @MedStar Health presents at #DAVALung on current & emerging therapies in thymic carcinoma, spotlighting platinum-doublet + ramucirumab as a new SOC and the evolving role of ICIs with key irAE management insights #ThymicCarcinoma #ImmunoOnc
Dr. Anjali Rohatagi from @SitemanCancer presentation at #DavaLung Summit on Trop2 expression is enriched in TETs, especially thymic carcinoma. SG & NMR-based biomarker strategies show promise in this rare disease space #ThymicCancer #Oncology #LungCancer #DAVALung
Dr. Anjali Rohtagi discusses the ongoing trial utilizing sacituzumab govitecan in advanced thymoma and thymic carcinoma at @Georgetown and @StanfordMed under PI Dr. @chulkimMD . Shout out to Dr. @HwakeleeMD as site PI. #DAVALung #HawaiiiLung25 #thymsm @Itmig_society
Dr. @chulkimMD highlights 1L carbo+pac+rami in thymic carcinoma as the new standard of care. While some data for use of chemoIO upfront, high rates here of immune related adverse events! @HwakeleeMD #DAVALung #HawaiiiLung25 #thymsm @Itmig_society
#HawaiiLung25 @chulkimMD @Georgetown discusses #thymiccarcinoma therapies-incorporating IO and VEGF therapies ➡️ RELEVENT- phase 2 carbo taxol + ramucirumab (OR 57%) @DAVAOnc
Clear survival gains in treating lung cancer reflected in this @NEJM article. All pts with lung cancer treated in public hospitals in France show median survival improved from 8.5 months in 2000 to 20.7 months in 2020. No room for nihilism anymore! evidence.nejm.org/doi/full/10.10…
I am extremely thankful for the entire RAMOSE trial team, co-investigators, @hoosiercancer HCRN , clinical research staff, and pts/families to complete this large multi-center randomized investigator-initiated trial (IIT) in #EGFR #lungcancer. We will report OS and other…
At #DAVALung, Dr. Xiuning Le (@LeXiuning, @MDAndersonNews) presented RAMOSE trial updates: ramucirumab + osimertinib improved PFS to 22.3m vs 16.1m with osimertinib alone (HR 0.56) in EGFR-mutant NSCLC. Benefit consistent across subgroups; toxicity manageable.
Dr. @lungoncdoc of @MDAndersonNews emphasizes MCED tests complement, but do NOT replace, existing screening guidelines. Follow-up after ➕MCED test requires a standardized process and must be accessible and affordable #lcsm #davalung #HawaiiLung25 #lcam
At #DAVALung, Dr. Xiuning Le (@LeXiuning, @MDAndersonNews) presented RAMOSE trial updates: ramucirumab + osimertinib improved PFS to 22.3m vs 16.1m with osimertinib alone (HR 0.56) in EGFR-mutant NSCLC. Benefit consistent across subgroups; toxicity manageable.